Evidence map›Paper›PMID 34440612›Full record

ArticleCells2021

Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays.

Sebastian Köppert, Carla Wolf, Noémi Becza, Giuseppe A Sautto, Fridolin Franke, Stefanie Kuerten, Ted M Ross, Paul V Lehmann, Greg A Kirchenbaum

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Extending ImmunoSpotVaccines · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sebastian KöppertResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA.
Carla WolfResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA.
Noémi BeczaResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA.
Giuseppe A SauttoCenter for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0002-0273-2235
Fridolin FrankeResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA.
Stefanie KuertenInstitute of Anatomy and Cell Biology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0001-6119-605X
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0003-1947-7469
Paul V LehmannResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA.
Greg A KirchenbaumResearch & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA.ORCID 0000-0001-6463-7623
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Georgia · USUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessment of humoral immunity to SARS-CoV-2 and other infectious agents is typically restricted to detecting antigen-specific antibodies in the serum. Rarely does immune monitoring entail assessment of the memory B-cell compartment itself, although it is these cells that engage in secondary antibody responses capable of mediating immune protection when pre-existing antibodies fail to prevent re-infection. There are few techniques that are capable of detecting rare antigen-specific B cells while also providing information regarding their relative abundance, class/subclass usage and functional affinity. In theory, the ELISPOT/FluoroSpot (collectively ImmunoSpot) assay platform is ideally suited for antigen-specific B-cell assessments since it provides this information at single-cell resolution for individual antibody-secreting cells (ASC). Here, we tested the hypothesis that antigen-coating efficiency could be universally improved across a diverse set of viral antigens if the standard direct (non-specific, low affinity) antigen absorption to the membrane was substituted by high-affinity capture. Specifically, we report an enhancement in assay sensitivity and a reduction in required protein concentrations through the capture of recombinant proteins via their encoded hexahistidine (6XHis) affinity tag. Affinity tag antigen coating enabled detection of SARS-CoV-2 Spike receptor binding domain (RBD)-reactive ASC, and also significantly improved assay performance using additional control antigens. Collectively, establishment of a universal antigen-coating approach streamlines characterization of the memory B-cell compartment after SARS-CoV-2 infection or COVID-19 vaccinations, and facilitates high-throughput immune-monitoring efforts of large donor cohorts in general.

Indexed as

Immunologic MemoryAnimalsAntigens, ViralB-LymphocytesCOVID-19Enzyme-Linked Immunospot AssayHistidineHumansMiceOligopeptidesSARS-CoV-2Viral ProteinsAntigens, ViralHis-His-His-His-His-HisHistidineOligopeptidesViral Proteinsantibody-secreting cellantigen coatingEBVfluorospotHCMVimmune monitoringinfluenzamemory B cellplasmablastSARS-CoV-2

Identifiers

PMID34440612
PMCPMC8394687
OpenAlexW3185348133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.